HHlevo-M Kid Suspension is a pediatric formulation combining Levocetirizine dihydrochloride (2.5 mg/5 ml) and Montelukast sodium (4 mg/5 ml), designed for the management of allergic conditions in children. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby alleviating symptoms such as rhinorrhea, sneezing, nasal congestion, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, reducing airway inflammation and bronchoconstriction, which is beneficial in the prophylaxis and treatment of asthma and allergic rhinitis. The combination provides a synergistic effect, addressing multiple pathophysiological pathways involved in allergic responses. HHlevo-M Kid Suspension is indicated for pediatric patients requiring symptomatic relief from allergic rhinitis, chronic urticaria, and mild to moderate asthma. The suspension form ensures ease of administration and accurate dosing in children. It is generally well tolerated; common adverse effects may include headache, somnolence, and gastrointestinal disturbances. Use should be guided by a healthcare professional, with attention to contraindications such as hypersensitivity to components. HHlevo-M Kid Suspension offers an effective therapeutic option for comprehensive allergy management in the pediatric population.